Supplementary Table 3. Logistic regression analysis to determine variables associated with good responders to SGLT2 inhibitors in overall patients

| Variable                                      | Odds ratio | 95% CI       | P value |
|-----------------------------------------------|------------|--------------|---------|
| **Univariate**                                |            |              |         |
| Age, yr                                       | 0.99       | 0.97–1.00    | 0.125   |
| Female sex                                    | 1.06       | 0.71–1.58    | 0.772   |
| Body mass index, kg/m²                        | 1.03       | 0.98–1.08    | 0.265   |
| Duration of diabetes, yr                      | 0.98       | 0.96–1.00    | 0.092   |
| Subtype of SGLT2 inhibitor (dapagliflozin)    | 1.04       | 0.64–1.70    | 0.878   |
| Baseline HbA1c, %                             | 1.50       | 1.25–1.80    | <0.001  |
| Baseline FPG, mg/dL                           | 1.01       | 1.00–1.01    | 0.016   |
| Baseline HOMA-β                               | 1.00       | 0.98–1.03    | 0.667   |
| Baseline HOMA-IR                              | 1.44       | 0.96–2.17    | 0.077   |
| Baseline eGFR, mL/min/1.73 m²                 | 1.01       | 1.00–1.02    | 0.139   |
| No insulin therapy                            | 1.56       | 1.03–2.35    | 0.035   |
| **Multivariate**                              |            |              |         |
| Baseline HbA1c, %                             | 1.84       | 1.48–2.29    | <0.001  |
| No insulin therapy                            | 2.91       | 1.77–4.78    | <0.001  |

SGLT2, sodium-glucose cotransporter-2; CI, confidence interval; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; HOMA-β, homeostasis model assessment of β-cell function; HOMA-IR, homeostasis model assessment of insulin resistance; eGFR, estimated glomerular filtration rate.